R 102380
Latest Information Update: 20 May 2003
At a glance
- Originator Sankyo
 - Class Antihyperglycaemics; Thiazolidinediones
 - Mechanism of Action
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- No development reported Diabetes mellitus
 
Most Recent Events
- 20 May 2003 No development reported - Preclinical for Diabetes mellitus in Japan (unspecified route)
 - 15 Feb 2000 Preclinical development for Diabetes mellitus in Japan (Unknown route)